Plain-English translation of NCT07934537 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This study is for people with a type of blood cancer called large B-cell lymphoma that has a specific genetic mutation (TP53) making it harder to treat. After you receive CAR-T cell therapy—a treatment that uses your own immune cells to fight cancer—you would take two medications together: chidamide (a tablet by mouth) and a PD-1 inhibitor (given through an IV). The study wants to see if this combination can keep your cancer from coming back and is safe for you.
Some patients experience their cancer returning after CAR-T therapy, which is a serious problem. This medication combination is designed to work with your immune system after CAR-T treatment to help prevent that relapse, especially in patients whose cancer has this particular genetic mutation.
You likely qualify if…
You likely don't qualify if…
You would first receive CAR-T cell therapy as planned with your doctor. After that infusion, you would begin taking chidamide as a tablet by mouth and receiving the PD-1 inhibitor through an IV infusion. Your doctor will monitor you closely with regular visits and tests to check how well the treatment is working and watch for any side effects. The treatment continues until your cancer progresses, you experience unacceptable side effects, or you and your doctor decide to stop.
AI-generated summary from trial data · Nov 14, 2026 · Not medical advice
China